Mittwoch, 21. April 2021
Navigation öffnen
Anzeige:
Imfinzi NSCLC
Imfinzi NSCLC
Fachinformation
JOURNAL ONKOLOGIE – STUDIE

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)

Rekrutierend

NCT-Nummer:
NCT02628067

Studienbeginn:
Dezember 2015

Letztes Update:
03.03.2021

Wirkstoff:
Pembrolizumab

Indikation (Clinical Trials):
Carcinoma, Small Cell Lung Carcinoma, Endometrial Neoplasms, Thyroid Neoplasms, Mesothelioma, Neuroendocrine Tumors, Cholangiocarcinoma, Salivary Gland Neoplasms, Colorectal Neoplasms, Carcinoid Tumor, Anus Neoplasms, Bile Duct Neoplasms, Vulvar Neoplasms, Thyroid Diseases, Neoplasms

Geschlecht:
Alle

Altersgruppe:
Erwachsene (18+)

Phase:
Phase 2

Sponsor:
Merck Sharp & Dohme Corp.

Collaborator:
-

Studienleiter

Medical Director
Study Director
Merck Sharp & Dohme Corp.

Kontakt

Studienlocations
(3 von 31)

Call for Information (Investigational Site 0018)
91010 Duarte
United StatesRekrutierend» Google-Maps
Call for Information (Investigational Site 0202)
90033 Los Angeles
United StatesRekrutierend» Google-Maps
Call for Information (Investigational Site 0017)
90048 Los Angeles
United StatesRekrutierend» Google-Maps
Call for Information (Investigational Site 0015)
32806 Orlando
United StatesRekrutierend» Google-Maps
Call for Information (Investigational Site 0011)
21231 Baltimore
United StatesRekrutierend» Google-Maps
Call for Information (Investigational Site 0005)
20850 Rockville
United StatesRekrutierend» Google-Maps
Call for Information (Investigational Site 0207)
02114 Boston
United StatesRekrutierend» Google-Maps
Call for Information (Investigational Site 0010)
02215 Boston
United StatesRekrutierend» Google-Maps
Call for Information (Investigational Site 0209)
02215 Boston
United StatesRekrutierend» Google-Maps
Call for Information (Investigational Site 0008)
08903 New Brunswick
United StatesRekrutierend» Google-Maps
Call for Information (Investigational Site 0004)
77030 Houston
United StatesRekrutierend» Google-Maps
Merck Canada
H9H 4M7 Kirkland
CanadaRekrutierend» Google-Maps
Ansprechpartner:
Medical Information Centre Centre d'information medicale Merck Canada Inc.
Phone: 514-428-8600 / 1-800-567-2594» Ansprechpartner anzeigen
Alle anzeigen

Studien-Informationen

Brief Summary:

In this study, participants with multiple types of advanced (unresectable and/or metastatic)

solid tumors who have progressed on standard of care therapy will be treated with

pembrolizumab (MK-3475).

Ein-/Ausschlusskriterien

Inclusion Criteria:

- Histologically or cytologically-documented, advanced solid tumor of one of the following

types:

- Anal Squamous Cell Carcinoma

- Biliary Adenocarcinoma (gallbladder or biliary tree (intrahepatic or extrahepatic

cholangiocarcinoma) except Ampulla of Vater cancers)

- Neuroendocrine Tumors (well- and moderately-differentiated) of the lung, appendix,

small intestine, colon, rectum, or pancreas

- Endometrial Carcinoma (sarcomas and mesenchymal tumors are excluded)

- Cervical Squamous Cell Carcinoma

- Vulvar Squamous Cell Carcinoma

- Small Cell Lung Carcinoma

- Mesothelioma

- Thyroid Carcinoma

- Salivary Gland Carcinoma (sarcomas and mesenchymal tumors are excluded)

- Any advanced solid tumor, with the exception of colorectal carcinoma (CRC), which is

Microsatellite Instability (MSI)-High (MSI-H) OR

- Any advanced solid tumor (including Colorectal Carcinoma [CRC]) which is Mismatch

Repair Deficient (dMMR)/MSI-H in participants from mainland China who are of Chinese

descent. (CRC participants will have a histologically proven locally advanced

unresectable or metastatic CRC which is dMMR/MSI-H that has received 2 prior lines of

therapy.) OR

- Any advanced solid tumor that has failed at least one line of therapy and is TMB-H

(≥10 mut/Mb, F1CDx assay), excluding dMMR/MSI-H tumors.

Note: For participants to be eligible for enrollment they must have failed at least one

line of standard of care systemic therapy (ie, not treatment naïve), with the exception of

CRC participants who must have failed at least 2 lines of standard of care systemic

therapy, as per CRC specific eligibility criteria. Participants must not have melanoma or

NSCLC.

- Progression of tumor or intolerance to therapies known to provide clinical benefit.

There is no limit to the number of prior treatment regimens

- Can supply tumor tissue for study analyses (dependent on tumor type)

- Radiologically-measurable disease

- Performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG)

Performance Scale within 3 days prior to first dose of pembrolizumab

- Life expectancy of at least 3 months

- Adequate organ function

- Female participants of childbearing potential must be willing to use adequate

contraception for the course of the study through 120 days after the last dose of

study treatment

- Male participants with partners of must childbearing potential must be willing to use

adequate contraception for the course of the study through 120 days after the last

dose of study treatment

Exclusion Criteria:

- Currently participating and receiving study therapy or has participated in a study of

an investigational agent and received study therapy or used an investigational device

within 4 weeks of the first dose of study treatment

- Diagnosis of immunodeficiency or receiving systemic steroid therapy or any other form

of immunosuppressive therapy within 7 days prior to the first dose of study treatment

- Active autoimmune disease that has required systemic treatment in the past 2 years

- Prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study Day 1 or not

recovered from an adverse event caused by mAbs administered more than 4 weeks earlier

- Prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2

weeks of study Day 1 or not recovered from adverse events caused by a previously

administered agent

- Known additional malignancy within 2 years prior to enrollment with the exception of

curatively treated basal cell carcinoma of the skin, squamous cell carcinoma of the

skin and/or curatively resected in situ cancers

- Known active central nervous system (CNS) metastases and/or carcinomatous meningitis

- Has known glioblastoma multiforme of the brain stem

- History of non-infectious pneumonitis that required steroids or current pneumonitis

- Active infection requiring systemic therapy

- Known psychiatric or substance abuse disorders that would interfere with the

participant's ability to cooperate with the requirements of the study

- Pregnant, breastfeeding, or expecting to conceive or father children within the

projected duration of the study, starting with the screening visit through 120 days

after the last dose of study treatment

- Previously participated in any other pembrolizumab (MK-3475) study, or received prior

therapy with an anti-programmed cell death (PD)-1, anti-PD-Ligand 1 (anti-PD-L1),

anti-PD-Ligand 2 (anti-PD-L2), or any other immunomodulating mAb or drug specifically

targeting T-cell co-stimulation or checkpoint pathways

- Known history of Human Immunodeficiency Virus (HIV)

- Known active Hepatitis B or C

- Received live vaccine within 30 days of planned start of study treatment

- Has severe hypersensitivity (≥Grade 3) to pembrolizumab and/or any of its excipients

- Known history of active tuberculosis (TB, Bacillus tuberculosis)

- Has had an allogenic tissue/solid organ transplant.

Studien-Rationale

Primary outcome:

1. Objective Response Rate (ORR) (Time Frame - Up to approximately 2 years):
ORR is defined as the percentage of participants who have a Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ at any time during the trial. Responses will be determined by independent central radiologic review, with confirmatory assessment as required per RECIST 1.1. Participants with unknown or missing response information will be treated as non-responders. The percentage of participants who experience a CR or PR based on modified RECIST 1.1 will be presented.



Secondary outcome:

1. Duration of Response (DOR) (Time Frame - Up to approximately 2 years):
DOR, defined in the subset of participants with a CR or PR, based on RECIST 1.1 as assessed by independent central radiologic review, as the time from first documented evidence of CR or PR until the first documented sign of disease progression or death due to any cause, whichever occurs first. A Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: At least a 30% decrease in the sum of diameters of target lesions) per RECIST 1.1 modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ. Participants who are alive, have not progressed, have not initiated new anti-cancer treatment, and have not been determined to be lost to follow-up are considered ongoing responders at the time of analysis.

2. Progression Free Survival (PFS) (Time Frame - Up to approximately 2 years):
PFS is defined as the time from allocation to the first documented disease progression according to RECIST 1.1 as assessed by independent central radiologic review, or death due to any cause, whichever occurs first. Per RECIST 1.1, PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. Note: The appearance of one or more new lesions is also considered PD. If a participant does not have a documented date of progression or death, PFS will be censored at the date of the last adequate assessment.

3. Overall Survival (OS) (Time Frame - Up to approximately 2 years):
OS was defined as the time from randomization to death due to any cause. OS is presented. Censoring will be performed using the date of last known contact for those who are alive at the time of analysis.

Studien-Arme

  • Experimental: Pembrolizumab 200 mg
    Participants receive pembrolizumab 200 mg intravenously on Day 1 of each 3-week cycle for up to 35 administrations (up to approximately 2 years of treatment).
  • Experimental: Pembrolizumab 400 mg
    Participants with any advanced solid tumor that has failed at least one line of therapy and is Tumor- Mutational Burden-High (TMB-H), excluding participants with mismatch repair deficient (dMMR/MSI-H) tumors. The dosing regimen for this cohort will be 400 mg every 6 weeks (Q6W) for up to 18 administrations (up to approximately 2 years of treatment).

Geprüfte Regime

  • pembrolizumab (MK-3475 / SCH 900475 / KEYTRUDA® / ):
    intravenous infusion
  • pembrolizumab (MK-3475 / SCH 900475 / KEYTRUDA® / ):
    intravenous infusion

Quelle: ClinicalTrials.gov


Das könnte Sie auch interessieren
Junge Menschen vor Gebärmutterhalskrebs und anderen Krebsarten schützen
Junge+Menschen+vor+Geb%C3%A4rmutterhalskrebs+und+anderen+Krebsarten+sch%C3%BCtzen
© Jochen Schönfeld / Fotolia.com

Die Ständige Impfkommission (STIKO) hat die Impfempfehlungen zur HPV-Impfung erweitert. Während es die offizielle Empfehlung für Mädchen bereits seit dem Jahr 2007 gibt, empfiehlt sie die HPV-Impfung seit diesem Jahr auch für Jungen. Um auf die Wichtigkeit der HPV-Impfung hinzuweisen, hat die Bundeszentrale für gesundheitliche Aufklärung (BZgA) Informationsmaterialien entwickelt, die derzeit an die...

Seltene Krebsarten – Stiefkind der Krebsforschung?
Seltene+Krebsarten+%E2%80%93+Stiefkind+der+Krebsforschung%3F
© Darren Baker / Fotolia.com

Eine seltene Krebsart bringt nicht nur Patienten, sondern auch Ärzte an ihre Grenzen. Dabei sind seltene Krebsarten gar nicht so selten wie die Bezeichnung vermuten lässt. Rund 100.000 Menschen erkranken in Deutschland jedes Jahr an einer solchen Krebserkrankung. Im aktuellen Monatsthema stellt das ONKO-Internetportal die wichtigsten seltenen Krebsarten, die damit verbundenen Herausforderungen bei der Therapie sowie Initiativen...

Klinische Studien in der Krebstherapie – Informationen für Patienten
Klinische+Studien+in+der+Krebstherapie+%E2%80%93+Informationen+f%C3%BCr+Patienten
© Alexander Raths / Fotolia.com

Für Krebspatienten ist die Teilnahme an einer Studie mit der Chance verbunden, frühzeitig Zugang zu innovativen Behandlungsmethoden zu bekommen, die im klinischen Alltag nicht erhältlich sind. Neue Wirkstoffe bieten viele Chancen, können aber auch unbekannte Risiken und Nebenwirkungen mit sich bringen. Das ONKO-Internetportal erläutert, welche Arten von Studien es in der Krebstherapie gibt und was Patienten, die sich...

Junge Krebspatienten: Ausbildung und Familie, aber auch Angst und Schmerzen
Junge+Krebspatienten%3A+Ausbildung+und+Familie%2C+aber+auch+Angst+und+Schmerzen
© pathdoc / Fotolia.com

„Ich hatte große Träume für mein Leben, jetzt denke ich oft viel, viel kurzfristiger“, sagt die 25-jährige Studentin Mia*, die vor anderthalb Jahren an Krebs erkrankte. Nach der Diagnose musste sie ihr Studium unterbrechen, ihre Familienplanung in Frage stellen und auch mit ihrem Freundeskreis einen neuen Umgang finden. Sie ist eine von rund 15.000 jungen Menschen, die jährlich im Alter von 18 bis 39 Jahren...